# Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants

> **NCT02064907** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 52 (actual)

## Conditions studied

- Bioavailability

## Interventions

- **DRUG:** Dexlansoprazole Delayed Release Orally Disintegrating Tablets
- **DRUG:** Dexlansoprazole Delayed Release Capsules

## Key facts

- **NCT ID:** NCT02064907
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-03
- **Final completion:** 2014-04
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2015-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02064907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02064907, "Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02064907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*